Skip to content
Triangle logo TriangleGet started
← Full study record

NCT05255601 · OUTCOME

Maximum Serum Concentration (Cmax)

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma · Source last updated 2026-06-26

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
GEOMETRIC_MEAN
Unit
ug/mL
Interval / dispersion
Geometric Coefficient of Variation
Time frame
Cycle 1 Day 1

What was measured

Maximum observed serum concentration of Analyte BMS-986016

Analysis population: PK Population

Groups in this outcome

Part A - Flat Dosing (AF)

Participants received treatment with Relatlimab 160 mg + Nivolumab 480 mg Q4W

Part A - Age/Weight-based Dosing (AW)

Participant received treatment with Relatlimab 2 mg/kg + Nivolumab 6 mg/kg Q4W

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Part A - Flat Dosing (AF)4
Part A - Age/Weight-based Dosing (AW)1

Reported measurements

Source class 1
Values in ug/mL · Interval/dispersion: Geometric Coefficient of Variation
GroupValueSpreadLowerUpperComment
Part A - Flat Dosing (AF)51.8316Not reportedNot reportedNot reported
Part A - Age/Weight-based Dosing (AW)40.00NANot reportedNot reportedUnable to calculate geometric coefficient of variation due to low number of participants
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        16
        value
        51.83
      2. comment
        Unable to calculate geometric coefficient of variation due to low number of participants
        group Id
        OG001
        spread
        NA
        value
        40.00
denoms
  1. counts
    1. group Id
      OG000
      value
      4
    2. group Id
      OG001
      value
      1
    units
    Participants
description
Maximum observed serum concentration of Analyte BMS-986016
dispersion Type
Geometric Coefficient of Variation
groups
  1. description
    Participants received treatment with Relatlimab 160 mg + Nivolumab 480 mg Q4W
    id
    OG000
    title
    Part A - Flat Dosing (AF)
  2. description
    Participant received treatment with Relatlimab 2 mg/kg + Nivolumab 6 mg/kg Q4W
    id
    OG001
    title
    Part A - Age/Weight-based Dosing (AW)
param Type
GEOMETRIC_MEAN
population Description
PK Population
reporting Status
POSTED
time Frame
Cycle 1 Day 1
title
Maximum Serum Concentration (Cmax)
type
PRIMARY
unit Of Measure
ug/mL

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice